Cariprazine – Mechanism of Action | Psychopharmacology | Clinical Application
Cariprazine is an atypical antipsychotic medication with a unique pharmacological profile and various clinical applications.
It is a dopamine D3/D2 receptor partial agonist and a serotonin 5-HT1A receptor partial agonist with a high affinity for D3 receptors.
Cariprazine is a third-generation antipsychotic used to treat a wide range of psychiatric disorders, from schizophrenia to bipolar disorder and major depressive disorder.
It has been found to be effective in the treatment of both positive and negative symptoms of schizophrenia, as well as in the treatment of bipolar disorder and depression.
Additionally, cariprazine has been found to be safe and well-tolerated with minimal side effects and a low risk of metabolic syndrome and weight gain.
Cariprazine’s unique pharmacological profile and clinical applications make it an attractive treatment option for many conditions.
Cariprazine (Vraylar, Reagila) was approved in September 2015 to treat schizophrenia and for the acute treatment of manic or mixed episodes associated with bipolar I disorder as monotherapy. [McCormack 2015]
Cariprazine was also recently approved in the U.S. for use as an adjunctive therapy to antidepressants for the treatment of MDD in adults. [It is not approved in Australia for this indication).
Cariprazine, or N-alkylpiperazine, is an organic compound consisting of a phenyl group bound to a piperazine skeleton. [Citrome 2013]
Fagiolini, A., Alcalá, J. Á., Aubel, T., Bienkiewicz, W., Bogren, M. M. K., Gago, J., … & Vernaleken, I. B. (2020). Treating schizophrenia with cariprazine: from clinical research to clinical practice. Real world experiences and recommendations from an International Panel. Annals of General Psychiatry, 19(1), 1-11.